New Age Alpha Advisors LLC Buys New Position in Artivion, Inc. (NYSE:AORT)

New Age Alpha Advisors LLC bought a new stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 52,223 shares of the company's stock, valued at approximately $1,493,000. New Age Alpha Advisors LLC owned about 0.12% of Artivion at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Wellington Management Group LLP grew its holdings in shares of Artivion by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company's stock worth $44,090,000 after acquiring an additional 46,267 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Artivion by 2.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 358,192 shares of the company's stock worth $10,241,000 after buying an additional 8,343 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Artivion by 58.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company's stock valued at $9,074,000 after purchasing an additional 125,668 shares during the period. Lord Abbett & CO. LLC bought a new stake in shares of Artivion in the third quarter valued at approximately $5,798,000. Finally, Principal Financial Group Inc. lifted its position in shares of Artivion by 3.8% in the 4th quarter. Principal Financial Group Inc. now owns 202,028 shares of the company's stock worth $5,776,000 after acquiring an additional 7,398 shares during the period. Institutional investors and hedge funds own 86.37% of the company's stock.

Remove Ads

Insider Activity at Artivion

In other news, CFO Lance A. Berry sold 3,259 shares of Artivion stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $89,003.29. Following the transaction, the chief financial officer now directly owns 75,805 shares of the company's stock, valued at $2,070,234.55. The trade was a 4.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jean F. Holloway sold 5,335 shares of Artivion stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $145,698.85. Following the sale, the senior vice president now owns 149,799 shares in the company, valued at approximately $4,091,010.69. The trade was a 3.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 90,799 shares of company stock worth $2,356,223 in the last three months. 8.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on AORT shares. JMP Securities reaffirmed a "market outperform" rating and set a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Stifel Nicolaus dropped their price objective on Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a research note on Tuesday, February 25th. Finally, Needham & Company LLC decreased their price objective on Artivion from $34.00 to $32.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $31.40.

Artivion Price Performance

Artivion stock traded down $0.72 during midday trading on Friday, reaching $23.42. The company's stock had a trading volume of 85,051 shares, compared to its average volume of 438,934. The stock has a market cap of $984.76 million, a PE ratio of -1,168.10 and a beta of 1.79. Artivion, Inc. has a 52 week low of $19.36 and a 52 week high of $32.33. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The business has a 50-day moving average price of $27.08 and a 200-day moving average price of $27.60.

Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). The firm had revenue of $97.31 million during the quarter, compared to analysts' expectations of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. On average, sell-side analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.